Fulcrum appoints new Chief Medical and new Chief Scientific officers

Fulcrum Therapeutics announced the appointment of Santiago Arroyo, as Chief Medical Officer, and Jeff W. Jacobs, as Chief Scientific Officer. Arroyo brings to Fulcrum nearly 20 years of biopharmaceutical industry experience, leading the clinical development of therapeutics across multiple disease areas. In his role as Chief Medical Officer at Momenta Pharmaceuticals, Dr. Arroyo led the clinical development of the company’s broad portfolio of hematology, neurology, immunology, and materno-fetal therapeutics. Previously, he was the Chief Medical Officer of Boston Pharmaceuticals. Jacobs has more than 25 years of experience in drug discovery and target identification, and has led, co-led and mentored multiple discovery programs from concept stage through development candidate nomination, and from investigational new drug enabling studies through to pivotal clinical trials. Jacobs was most recently Chief Scientific Officer at Goldfinch Bio, where he led the research and discovery program to help build its portfolio of therapeutics for rare kidney diseases. Before Goldfinch, Jacobs held roles of increasing responsibilities at Ardelyx, and was promoted to Chief Scientific Officer.